We are lucky in our choice of legal representation
Post# of 147892
(Total Views: 564)
Posted On: 12/11/2021 6:50:16 PM
We are lucky in our choice of legal representation and who we chose. Nader or maybe the Board of Directors have been making great choices lately it would seem also with the newest choice of PPD as our new CRO for our Mono HIV BLA.
This HIV mono indication is the one BLA that will shine bright for us. We know already we have the p value and efficacy to get approval. We finished our trial. We just need the help of an experienced CRO to cross that finish line. We are lucky we picked a giant of the industry to get us there. Things are looking so bright for our future. No more dilly-dallying around. Go big or go home as they now say.
How many approvals could we have this year? Two Covid EUA’s, Two Cancer BTD’s and two HIV BLA’s and throw in a nice huge Nash BTD for good measure… all in 2022… possibly 7 approvals? WOW! Is this year the year for the platform drug Vyrologix? Household name by end of 2023? Good times for a future platform drug. How can we temper our excitement? I can’t do it… forgive me for dreaming a little… it’s all entirely possible. Say we only get half of those approvals… still a great year and we kill it again in 2023. If we are like Truvada. They average 6 indications approved each year on their platform MAB drug… Hmmm… oh to dream of potential like that.
This HIV mono indication is the one BLA that will shine bright for us. We know already we have the p value and efficacy to get approval. We finished our trial. We just need the help of an experienced CRO to cross that finish line. We are lucky we picked a giant of the industry to get us there. Things are looking so bright for our future. No more dilly-dallying around. Go big or go home as they now say.
How many approvals could we have this year? Two Covid EUA’s, Two Cancer BTD’s and two HIV BLA’s and throw in a nice huge Nash BTD for good measure… all in 2022… possibly 7 approvals? WOW! Is this year the year for the platform drug Vyrologix? Household name by end of 2023? Good times for a future platform drug. How can we temper our excitement? I can’t do it… forgive me for dreaming a little… it’s all entirely possible. Say we only get half of those approvals… still a great year and we kill it again in 2023. If we are like Truvada. They average 6 indications approved each year on their platform MAB drug… Hmmm… oh to dream of potential like that.
(9)
(1)CytoDyn Inc (CYDY) Stock Research Links
Scroll down for more posts ▼